Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A steep one-year run has pushed Johnson & Johnson’s stock near new highs, raising the question of whether the company’s underlying fundamentals still offer room for returns at current levels.
THE APEX TIMES
THE APEX TIMES
A new market note points to strength in Johnson & Johnson’s drug pipeline and business quality, but argues the stock’s valuation still leaves investors exposed.
THE APEX TIMES
The company said new analyses presented in 12 neurology congress abstracts add to evidence of sustained disease control for IMAAVY in generalized myasthenia gravis, a chronic autoimmune condition.
THE APEX TIMES
A recent market round-up framed Bristol Myers Squibb as a specialty-medicine story trading at a discount, while positioning Johnson & Johnson as the steadier cash generator backed by top-tier margins.
THE APEX TIMES
The company said on June 11 that the TECNIS PureSee intraocular lens (IOL), an extended depth of focus technology used in cataract procedures, became available across the United States.
THE APEX TIMES
The stock ended the session up 1.61% to $244.88, following the trading session’s choppier tape.
THE APEX TIMES
Investors are preparing for Johnson & Johnson’s next earnings release after expectations pointed to modest growth in profit, as the company’s broad healthcare portfolio continues to be tested by pricing, costs, and demand swings across markets.
THE APEX TIMES
The company said its Dual Energy THERMOCOOL SMARTTOUCH SF platform is now available in Europe, aiming to broaden access to advanced catheter-based treatment for certain cardiac rhythm disorders.
THE APEX TIMES
A market rotation toward lower-volatility, dividend-paying companies put Johnson & Johnson (JNJ) and peers in focus, according to a Yahoo Finance roundup published June 23, 2026.
